Redsense Medical signs distribution agreement for Italy with Spindial

Report this content

Redsense Medical has signed a distribution agreement for Italy with its business partner Spindial, that was selected as one of the winners in a public procurement in Italy last autumn for over 3 million dialysis treatments. A first order is expected early in the third quarter. 

The finalisation of the result in the public procurement was delayed due to an appeal process, but the result is now final, and the necessary agreements have been signed by all parties. 

“I am pleased that Redsense will now be offered to many hemodialysis patients in Italy as a part of the country’s public health care system. Hopefully, this will inspire other European countries to roll out a wider use of Redsense to increase patient safety, safe lives and reduce health care costs,” says Redsense Medical’s CEO Patrik Byhmer.

The Italian public procurement contract covers more than 3 million hemodialysis treatments during 5 years in total. Spindial’s offer includes products from Redsense Medical and dialysis machines from Nikkiso that are directly compatible with Redsense.

The Italian market for hemodialysis consists of approximately 45 000 patients. Spindial S.p.A. is a family owned company that was founded in 2000, and has been delivering dialysis products and services on the Italian market since its inception. The company is a distributor of dialysis machine manufacturers, and Redsense collaboration partners, Nikkiso and NxStage Medical. 

For more information, please contact
Patrik Byhmer, CEO Redsense Medical AB (publ)
Telephone: +46 (0) 35 - 10 60 30

About Redsense Medical
Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense system, a medical technology product used for monitoring and alarm in the case of blood leakage in connection with hemodialysis. Redsense solves one of the most serious remaining safety problems within hemodialysis – to quickly detect venous needle dislodgement and catheter leakage and minimizing blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. The company has also developed an internationally standardized direct connection enabling compatible dialysis machines to stop the blood flow automatically when blood leakage occurs. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. 

This information is such information that Redsense Medical AB (publ) is obligated to publish in compliance with the EU market abuse regulation. This information was provided, through the above contact, for publication on the25 of June 2018.


Documents & Links